Fig. 6
From: Early administration of adalimumab for paediatric uveitis due to Behçet’s disease
Changes in anterior chamber cell grade (a) and prednisolone dose (b) in Case 2. Retinal vasculitis recurred in both eyes, and prednisolone was increased to 20 mg/day, while methotrexate was initiated at 6 mg. A maximum of 12 mg methotrexate was administered; however, the patient experienced nausea and the inflammation relapsed. After the patient was diagnosed with an incomplete type of Behçet’s disease by the paediatrician, adalimumab was introduced, and prednisolone was slowly tapered. The anterior chamber cell grade dramatically improved from 3+ in both eyes to 0 and 0.5+ in the right and left eyes, respectively, within 7 weeks after beginning administration of adalimumab. The inflammation subsided, and local and systemic corticosteroid therapies were discontinued